Browse the evidence

Increased circulating levels of branched-chain amino acids (BCAAs) and imidazole propionate, linked to gut microbiota function, are associated with insulin resistance and higher risk of type 2 diabetes.

High levels of certain metabolites like BCAAs and imidazole propionate in your blood are linked to insulin resistance. These are partly produced by your gut bacteria, suggesting that a balanced diet supporting a healthy microbiome is important for metabolic health.

Educational documentaries can significantly increase intentions to reduce meat consumption, but these increased intentions do not translate into reduced actual consumption.

You can watch a documentary and genuinely *want* to eat less meat, but that desire alone won't change your diet. The study shows that while intentions go up, actual eating habits stay the same. To bridge this gap, you need more than just motivation; you need a plan, recipes, and environmental support to turn that intention into action.

Newer GLP-1RAs achieve average weight loss of 15% or greater, but a substantial number of patients fail to achieve even 5% weight loss, and weight loss is lower in older adults, males, and those with type 2 diabetes.

If you are on a GLP-1RA and not losing weight, you are not alone. Older adults, men, and those with type 2 diabetes often lose less weight on average. Discuss this with your doctor to see if lifestyle adjustments or other strategies can help improve your response.

Obesity and metabolic syndrome significantly impair the anabolic response (lean mass and strength gains) to resistance exercise and protein supplementation in older adults, creating anabolic resistance that limits muscle recovery during weight management.

If you are older and have excess body fat or metabolic issues, standard resistance training and protein intake will be less effective at building muscle than they are for leaner individuals. This is due to 'anabolic resistance' caused by inflammation and insulin resistance. To overcome this, you likely need higher-quality protein sources (like whey/casein blends with creatine and omega-3s) rather than just any protein, and you must prioritize metabolic health improvements alongside training.

Higher doses of tirzepatide (10-15 mg), younger age, and female sex are associated with a longer time to reach a weight plateau compared to lower doses (5 mg), older age, and male sex.

If you are on tirzepatide and your weight loss slows down significantly (plateau), do not panic or assume the drug has stopped working. This is a normal physiological adaptation. The study shows that people on higher doses, younger people, and women tend to reach this plateau later because they lose more total weight. Focus on maintaining the negative energy balance rather than chasing rapid scale changes. If you are on a lower dose (5mg), you may plateau sooner than those on 10-15mg, but this does not mean the treatment is ineffective.

Four weeks of daily arachidonic acid (ARA) supplementation (1.5 g/day) does not enhance the acute muscle protein synthesis (MPS) or anabolic signaling response to resistance exercise in trained men, but it does stimulate ribosome biogenesis 48 hours post-exercise.

If you are a trained man taking 1.5g of Arachidonic Acid daily, do not expect it to increase your muscle growth immediately after your workout. The study shows it has no effect on the first 4 hours of recovery. However, it might help your muscles build more protein-making machinery (ribosomes) two days after your workout, which could support long-term adaptation. Focus on your training and protein intake for immediate results; ARA is not a quick fix.

Adherence to a high-carbohydrate diet (60% energy) for 14-20 weeks significantly increases regional cerebral blood flow in the nucleus accumbens (reward) and hypothalamus (homeostasis) compared to a low-carbohydrate diet (20% energy), suggesting neural mechanisms that may impede weight-loss maintenance.

If you are trying to maintain weight loss, the type of carbohydrates you eat matters for your brain's reward system. A diet high in carbohydrates (60% of calories) was shown to increase blood flow to the brain's reward and hunger centers compared to a low-carb diet (20% of calories). This neural activation may make it harder to stick to your diet long-term, even if you are eating the same number of calories. Consider reducing carbohydrate intake to lower levels to potentially dampen these reward-driven hunger signals.

Whole-room indirect calorimetry provides highly reliable measurements of daily energy expenditure components (sleep, 24-hour, basal, and resting EE) with intraclass correlation coefficients exceeding 90%, and this reliability is maintained even after significant weight loss.

If you are designing a study on weight loss or metabolic adaptation, whole-room indirect calorimetry is a highly reliable tool for measuring energy expenditure. To maximize efficiency and reduce the number of participants needed, use at least two days of measurement in the calorimeter rather than one, as this significantly improves the precision of detecting changes in energy expenditure.

The efficacy of GLP-1RA combined with lifestyle modification is influenced by treatment duration, drug type (semaglutide/tirzepatide), dosing frequency (weekly), and geographic region (North America).

For the best weight loss results with GLP-1RAs, choose a weekly formulation (like semaglutide or tirzepatide) if possible, maintain the treatment for at least a year, and ensure your lifestyle intervention is consistent. Regional factors may also play a role in outcomes.

A moderate increase in protein intake (from ~0.8 to ~1.2 g/kg/day) provides a small additional improvement in functional capacity (specifically longer walk tests) but does not improve muscle strength or lean mass quality in postmenopausal women following resistance exercise.

If you are a postmenopausal woman starting resistance training, aim for about 1.2 grams of protein per kilogram of body weight daily. This moderate increase over the standard recommendation (0.8 g/kg) may help you walk faster and perform daily tasks better, but it will not necessarily make your muscles stronger or larger compared to eating the standard amount. Focus on consistent resistance training.

Discontinuation rates for weight-reducing (WR) diabetes-specific medications are nearly twice as high as those for weight-inducing (WI) medications, indicating poor persistence with preferred therapies.

If you start a weight-reducing diabetes medication, be prepared for a higher chance of stopping it compared to older weight-gain drugs. This is common, so don't be discouraged. Talk to your doctor about managing side effects, starting with a lower dose, or switching to an oral formulation if injections are the issue. Persistence is key to seeing long-term benefits.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce hepatic steatosis and improve metabolic markers in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), but they do not significantly improve liver fibrosis.

GLP-1 medications like semaglutide and tirzepatide are effective at reducing liver fat and improving metabolic health in people with fatty liver disease. However, they do not currently appear to reverse liver scarring (fibrosis). While they offer significant benefits for steatosis and weight loss, patients should be aware of common gastrointestinal side effects and the current limitation regarding fibrosis reversal.

Dual or Triple Receptor Agonists (combining GLP-1, GIP, and/or Glucagon) offer superior reduction in liver fat and weight loss compared to selective GLP-1 receptor agonists alone.

Newer 'dual' and 'triple' hormone medications (like Tirzepatide or Efinopegdutide) appear to reduce liver fat and weight more effectively than older GLP-1 drugs alone. These are currently under investigation and may become the preferred treatment for MASLD, especially for those who need significant weight loss and liver fat reduction.

Gastrointestinal adverse events (nausea, vomiting, diarrhea, dyspepsia) associated with tirzepatide contribute minimally (up to 3.1%) to total weight reduction, with weight loss occurring similarly in patients with and without these symptoms.

Do not expect nausea or vomiting to drive your weight loss. Clinical data shows that patients who experience no gastrointestinal side effects lose just as much weight as those who do. Focus on the hormonal mechanism of the drug rather than tolerating discomfort as a sign of efficacy.

Fish oil supplementation (3.85 g/day EPA+DHA) combined with resistance training significantly increases absolute and relative upper-body strength and relative lower-body strength in young adults compared to placebo, without significantly altering lean body mass.

If you are a young, healthy adult doing resistance training 3 times a week, adding 3.85 grams of combined EPA and DHA daily (from fish oil) can help you get stronger, especially in your upper body and relative strength, without necessarily making you bigger. This effect is likely due to improved muscle quality and neural factors, not just muscle growth. Ensure you are getting enough protein (at least 1.2g/kg/day) as this may be required for the fish oil to work effectively.

Obesity increases the risk of nephrolithiasis (kidney stones) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, and sodium excretion, as well as insulin resistance.

Obesity increases your risk of kidney stones by changing your urine chemistry (making it more acidic and increasing stone-forming minerals). Maintaining a healthy weight helps normalize these urinary factors and reduces stone risk.

Weight reduction interventions, including lifestyle changes and ACE inhibition, reduce glomerular hyperfiltration and proteinuria in obese patients with CKD.

If you are overweight and have diabetes, losing weight through diet and exercise can cut your risk of developing kidney disease by 30%. This benefit comes from reducing the strain on your kidneys, not just from better blood sugar control.

Obesity increases the risk of kidney stones (nephrolithiasis) through lower urine pH, increased urinary oxalate, uric acid, and sodium excretion.

Obesity changes your urine chemistry, making you more likely to form kidney stones. This happens because your body excretes more acid and minerals like oxalate. Maintaining a healthy weight helps normalize these urinary factors and reduces stone risk.

Higher BMI is associated with increased feelings of being judged by primary care providers, which correlates with higher rates of avoiding healthcare visits due to weight-related concerns.

If you have a higher BMI, you may feel judged by doctors, and this feeling often stops you from going to appointments. This is a common reaction to stigma, not a reflection of your worth. To overcome this, look for providers who explicitly prioritize respectful communication and ask about your weight management goals proactively.

Food cravings and medical conditions limiting physical activity are the most frequent barriers to weight loss, with food cravings reported by 30.7%-49.9% of respondents.

Food cravings and physical limitations are the top barriers to weight loss for most people. These are common and can often be addressed through education and access to resources like dietitians and exercise facilities.

Implementing an intensive 18-month behavioral weight loss intervention in community mental health settings for adults with serious mental illness costs approximately $501 per kilogram of weight lost, or $95 per participant per month.

If you run a community mental health program, you can implement an 18-month weight loss program for about $95 per patient per month. The key is to use existing staff and kitchen budgets where possible, and to train your own staff to deliver the intervention to save on hiring external coaches. The cost per kilogram lost is competitive with commercial programs, making it a viable option for improving patient health.

An academia-industry partnership model for community-based controlled feeding studies enables high-fidelity macronutrient differentiation and long-term adherence, overcoming the feasibility and cost barriers of traditional hospital-based metabolic ward trials.

This paper does not offer a direct diet plan for individuals, but it validates that high-adherence dietary interventions are possible in real-world settings if logistical barriers are removed. For researchers or program designers, partnering with commercial food services (like Sodexo) allows for the creation of palatable, differentiated diets that participants can actually follow long-term. For individuals, the key takeaway is that removing the burden of meal planning and procurement (via meal delivery or similar services) significantly improves adherence to specific macronutrient targets.

GLP-1 receptor agonists (semaglutide) significantly improve quality of life and exercise capacity in obese patients with heart failure with preserved ejection fraction (HFpEF), primarily through substantial weight loss.

For obese patients with HFpEF, GLP-1 agonists like semaglutide are effective at improving quality of life and exercise capacity, largely by driving significant weight loss (approx. 13%). While these drugs are promising, their benefits appear closely tied to weight reduction rather than unique cardiac mechanisms. Therefore, they should be viewed as one option among others, including caloric restriction and supervised exercise, which may offer similar benefits at a lower long-term cost.

Once-weekly semaglutide (0.5 mg and 1.0 mg) as an add-on to metformin significantly improves glycemic control (HbA1c), reduces body weight, and lowers blood pressure compared to once-daily sitagliptin in patients with type 2 diabetes.

For patients with Type 2 Diabetes on metformin who need better blood sugar and weight control, switching to once-weekly semaglutide is more effective than switching to the oral drug sitagliptin. Semaglutide lowers HbA1c, weight, and blood pressure more significantly. However, be aware that semaglutide carries a higher risk of side effects and treatment discontinuation compared to sitagliptin.